Clinical implications for substandard, nonproprietary medicines in multiple sclerosis: focus on fingolimod
about
Clinical implications for substandard, nonproprietary medicines in multiple sclerosis: focus on fingolimod
description
2016 nî lūn-bûn
@nan
2016 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2016 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2016年の論文
@ja
2016年学术文章
@wuu
2016年学术文章
@zh-cn
2016年学术文章
@zh-hans
2016年学术文章
@zh-my
2016年学术文章
@zh-sg
2016年學術文章
@yue
name
Clinical implications for subs ...... sclerosis: focus on fingolimod
@ast
Clinical implications for subs ...... sclerosis: focus on fingolimod
@en
Clinical implications for subs ...... sclerosis: focus on fingolimod
@nl
type
label
Clinical implications for subs ...... sclerosis: focus on fingolimod
@ast
Clinical implications for subs ...... sclerosis: focus on fingolimod
@en
Clinical implications for subs ...... sclerosis: focus on fingolimod
@nl
prefLabel
Clinical implications for subs ...... sclerosis: focus on fingolimod
@ast
Clinical implications for subs ...... sclerosis: focus on fingolimod
@en
Clinical implications for subs ...... sclerosis: focus on fingolimod
@nl
P2093
P2860
P921
P3181
P356
P1476
Clinical implications for subs ...... sclerosis: focus on fingolimod
@en
P2093
Alexey Boyko
Erwin Chiquete
Jorge Barahona Strauch
Jorge Correale
Nadina Frider
Snezana Milojevic
P2860
P304
P3181
P356
10.2147/DDDT.S106802
P407
P50
P5008
P577
2016-06-30T00:00:00Z